Over a dozen ALK fusion partners have been identified in several cancer types1, 2, 3, 4, and this has ultimately led to clinical translation and United States Food and Drug Administration approval of ALK inhibitors5 as a first-line treatment for ALK-positive lung cancer patients. The gene discussed is ALK; the disease is cancer.